Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Schmitt

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Environmental Toxicology and Chemistry|July 26, 2011
Improving uncertainty analysis in kinetic evaluations using iteratively reweighted least squaresZhenglei Gao, John W Green, Jan Vanderborght, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2008
Whole body physiologically-based pharmacokinetic models: their use in clinical drug developmentAndrea N Edginton, Frank-Peter Theil, Walter Schmitt, et al.
Journal of Medicinal Chemistry|July 23, 2004
A physiological model for the estimation of the fraction dose absorbed in humansStefan Willmann, Walter Schmitt, Jörg Keldenich, et al.
Environmental Toxicology and Chemistry|July 16, 2015
A toxicokinetic and toxicodynamic modeling approach using Myriophyllum spicatum to predict effects caused by short-term exposure to a sulfonylureaSimon Heine, Frederik Schild, Walter Schmitt, et al.
Handbook of Experimental Pharmacology|November 19, 2015
Modeling and Simulation of In Vivo Drug EffectsJörg Lippert, Rolf Burghaus, Lars Kuepfer, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 14, 2007
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugsStefan Willmann, Karsten Höhn, Andrea Edginton, et al.
Pediatric Cardiology|May 9, 2024
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart FailureWalter Schmitt, Christian Diedrich, Taye H Hamza, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 3, 2018
Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating OxygenationSina Saffaran, Wenfei Wang, Anup Das, et al.
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
Integrated Environmental Assessment and Management|April 21, 2015
An example of population-level risk assessments for small mammals using individual-based population modelsWalter Schmitt, Domenica Auteri, Finn Bastiansen, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Environmental Toxicology and Chemistry|July 26, 2011
Improving uncertainty analysis in kinetic evaluations using iteratively reweighted least squaresZhenglei Gao, John W Green, Jan Vanderborght, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2008
Whole body physiologically-based pharmacokinetic models: their use in clinical drug developmentAndrea N Edginton, Frank-Peter Theil, Walter Schmitt, et al.
Journal of Medicinal Chemistry|July 23, 2004
A physiological model for the estimation of the fraction dose absorbed in humansStefan Willmann, Walter Schmitt, Jörg Keldenich, et al.
Environmental Toxicology and Chemistry|July 16, 2015
A toxicokinetic and toxicodynamic modeling approach using Myriophyllum spicatum to predict effects caused by short-term exposure to a sulfonylureaSimon Heine, Frederik Schild, Walter Schmitt, et al.
Handbook of Experimental Pharmacology|November 19, 2015
Modeling and Simulation of In Vivo Drug EffectsJörg Lippert, Rolf Burghaus, Lars Kuepfer, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 14, 2007
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugsStefan Willmann, Karsten Höhn, Andrea Edginton, et al.
Pediatric Cardiology|May 9, 2024
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart FailureWalter Schmitt, Christian Diedrich, Taye H Hamza, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 3, 2018
Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating OxygenationSina Saffaran, Wenfei Wang, Anup Das, et al.
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
Integrated Environmental Assessment and Management|April 21, 2015
An example of population-level risk assessments for small mammals using individual-based population modelsWalter Schmitt, Domenica Auteri, Finn Bastiansen, et al.
Pageof 3